• Japanese
  • Korean
  • Chinese
Cover Image

Ovarian Cancer Partnering 2010-2015

Provides understanding and access to the ovarian cancer partnering deals and agreements entered into by the worlds leading healthcare companies .

Description

The Ovarian Cancer Partnering 2010-2015 report provides understanding and access to the ovarian cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in ovarian cancer partnering deals

Top ovarian cancer deals by value

Deals listed by company A-Z, industry sector, stage of development, technology type

The Ovarian Cancer Partnering 2010-2015 provides understanding and access to the ovarian cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of ovarian cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors ovarian cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This data driven report contains over 100 links to online copies of actual ovarian cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of ovarian cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bladder cancer technologies and products.

Report scope

Ovarian cancer Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to ovarian cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

  • Trends in ovarian cancer dealmaking in the biopharma industry since 2010
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 100 ovarian cancer deals and contract documents where available
  • The leading ovarian cancer deals by value since 2010

In Ovarian cancer Partnering 2010-2015, the available deals are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Ovarian Cancer Partnering 2010-2015 provides the reader with the following key benefits:

  • In-depth understanding of ovarian cancer deal trends since 2010
  • Access to summary headline, upfront, milestone and royalty data
  • Comprehensive access to over 100 actual ovarian cancer deals entered into by the world's biopharma companies since 2010
  • Insight into key deal terms included in contracts, where disclosed
  • Understand the key deal terms companies have agreed in deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Ovarian cancer partnering

  • 2.1. Introduction
  • 2.2. Ovarian cancer partnering over the years
  • 2.3. Ovarian cancer partnering by deal type
  • 2.4. Ovarian cancer partnering industry sector
  • 2.5. Ovarian cancer partnering by stage of development
  • 2.6. Ovarian cancer partnering by technology type

Chapter 3 - Average deal terms for Ovarian cancer

  • 3.1 Introduction
  • 3.2 Average deal terms for Ovarian cancer
  • 3.3 Ovarian cancer headline values with median calculation
  • 3.4 Ovarian cancer upfront values with median calculation
  • 3.5 Ovarian cancer milestone values with median calculation
  • 3.6 Ovarian cancer royalty rates with median calculation

Chapter 4 - Active Ovarian cancer dealmakers

  • 4.1. Introduction
  • 4.2 Most active Ovarian cancer dealmakers
  • 4.3. Top Ovarian cancer deals by value
  • 4.4 Big pharma deal activity
  • 4.5 Big biotech deal activity

Chapter 5 - Ovarian cancer dealmaking directory

  • 5.1. Introduction
  • 5.2. Company A-Z
  • 5.3. By deal type
  • 5.4. By industry sector
  • 5.5. By stage of development
  • 5.6. By technology type

Chapter 6 - Partnering resource center

  • 6.1. Online partnering
  • 6.2. Partnering events
  • 6.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering
  • Order Form - Reports
  • Order Form - Subscription Access Products
  • Table of figures
  • Figure 1: Ovarian cancer partnering since 2010
  • Figure 2: Ovarian cancer dealmaking activity- 2010 to 2015
  • Figure 3: Ovarian cancer partnering by deal type since 2010
  • Figure 4: Ovarian cancer partnering by industry sector since 2010
  • Figure 5: Ovarian cancer partnering by stage of development since 2010
  • Figure 6: Ovarian cancer partnering by technology type since 2010
  • Figure 7: Ovarian cancer deals with a headline value
  • Figure 8: Ovarian cancer deals with upfront payment values
  • Figure 9: Ovarian cancer deals with milestone payments
  • Figure 10: Ovarian cancer deals with royalty rates, %
  • Figure 11: Top Ovarian cancer deals by value since 2010
  • Figure 12: Big pharma - top 50 - Ovarian cancer deals 2010 to 2015
  • Figure 13: Big pharma Ovarian cancer deal frequency - 2010 to 2015
  • Figure 14: Big biotech - top 50 - Ovarian cancer deals 2010 to 2015
  • Figure 15: Big biotech Ovarian cancer deal frequency - 2010 to 2015
  • Figure 16: Online partnering resources
  • Figure 17: Forthcoming partnering events
  • Figure 18: Deal type definitions
Show More
Pricing
  • Int'l: +1-860-674-8796
  • TollFree(US): +1-866-353-3335
  • Europe: +32-2-535-7543
  • Asia: +65-6223-2436
Back to Top